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COVID RESEARCH INEQUALITIES: HIGHLIGHTING THE NEED
FOR INCREASED MINORITY PARTICIPATION IN CLINICAL TRIALS
Olivia C. Perlstein*
I. INTRODUCTION
In March 2020, the world came to a screeching halt: people stopped
going to work and children stopped going to school; grocery and drug
stores displayed empty shelves where paper goods, cleaning supplies,
medicines, and pantry items were once fully stocked. Big cities, like New
York, felt almost post-apocalyptic: subways were empty, traffic had
thinned, and the piercing wail of ambulance sirens echoed through the
otherwise empty streets. Less than two months after the first confirmed
COVID-19 case in the United States, the World Health Organization
(WHO) declared COVID-19 a pandemic on March 11, 2020.1 COVID-19,
the disease caused by the novel coronavirus SARS-CoV-2, brought the
economy to a grinding halt, pushed the healthcare systems beyond
capacity, and as of October 2021, has caused more than 700,000 deaths
in the United States alone.2
Experts noted early on in the pandemic that certain factors, such as
preexisting conditions and geographic location, were associated with
greater infection and death rates.3 Data also shows that race or ethnicity
plays a role in susceptibility to COVID-19 and that racial and ethnic

* J.D. Candidate, 2022, Seton Hall University School of Law; B.S., University of
Massachusetts Amherst. I would like to thank my faculty advisor, Professor Carl
Coleman, for his guidance and support during the writing process.
1 AJMC Staff, A Timeline of COVID-19 Developments in 2020, AJMC (Jan. 1, 2021),
https://www.ajmc.com/view/a-timeline-of-covid19-developments-in-2020.
2 Id.; Nat’l Ctr. for Health Statistics, Daily Updates of Totals by Week and State, CTRS.
FOR DISEASE CONTROL & PREVENTION, https://www.cdc.gov/nchs/nvss/vsrr/COVID19/
index.htm.
3 Winston Morgan, Will the COVID-19 Pandemic and Black Lives Matter Change
Science and Society?, MED. NEWS TODAY (Aug. 20, 2020), https://www.medical
newstoday.com/articles/will-the-covid-19-pandemic-and-black-lives-matter-changescience-and-society; see Julius M. Wilder, The Disproportionate Impact of COVID-19 on
Racial and Ethnic Minorities in the United States, 72 CLINICAL INFECTIOUS DISEASES 709
(2021),
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa959/
5869621.
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disparities exist for both morbidity and mortality rates of COVID-19.4 A
review of COVID-19 cases in England found that Black and Asian
individuals are at a higher risk of COVID-19 mortality even when
controlling for factors such as age and comorbidity.5 This is consistent
with general knowledge of racial health disparities in the United States.6
In addition to the COVID-19 pandemic, 2020 saw widespread
support for the Black Lives Matter movement, sparked by outrage over
the public murder of George Floyd by Minneapolis police officers.7
Worldwide protests have called for an end to systemic racism, and the
protests have had some success with finally pressuring individuals,
politicians, and companies to recognize and reflect upon the injustices
and abuses faced by Black Americans.8 The convergence of the COVID19 pandemic and the power and prominence of the Black Lives Matter
movement provides the perfect sociopolitical climate to re-examine the
landscape of our healthcare system through the lens of racial equality,
particularly the field of clinical research.
Although minority communities are disproportionately affected by
COVID-19, both treatment and vaccine clinical trials have failed to enroll
sufficiently diverse participants.9 While the National Institutes of Health
(NIH) has issued regulations requiring minorities to be represented in
Phase III clinical trials receiving NIH funding, the U.S. Food and Drug
Administration (FDA), which oversees clinical trials of drugs and
medical devices, has merely issued non-binding guidance encouraging
diversity in clinical trial participants.10 These efforts have been largely
unsuccessful.11 This Comment will argue that to reduce racial
4 Morgan, supra note 3; Wilder, supra note 3, at 709 (“[Coronavirus] . . . has caused
a global pandemic and has highlighted the glaring impact of social determinants of
health and racism in the United States.”).
5 Morgan, supra note 3.
6 See infra Section II.A.
7 Austa Somvichian-Clausen, What the 2020 Black Lives Matter Protests Have
Achieved So Far, HILL (June 10, 2020), https://thehill.com/changing-america/respect/
equality/502121-what-the-2020-black-lives-matter-protests-have-achieved-so.
8 Id.
9 Wayne A. I. Frederick et al., Opinion, We Need to Recruit More Black Americans in
Vaccine Trials, N.Y. TIMES (Sept. 11, 2020), https://www.nytimes.com/2020/09/11/
opinion/vaccine-testing-black-americans.html (“[T]he largest population being killed
by Covid-19 should have a significant role in development of a treatment.”). Moderna
has reported 26 percent diversity despite minorities making up 32 percent of the
population, earning a “C” from Dr. Fauci. Id.
10 See infra Section IV.A.
11 See Vassia Barba, Female Participation Up, Diversity Rates Down in 2019 Approved
Drugs’ Trials, OUTSOURCING-PHARMA.COM (Feb. 26, 2020), https://www.outsourcingpharma.com/Article/2020/02/26/FDA-release-of-clinical-trials-participationdemographics (The FDA’s Drug Trials Snapshots report for 2019 “show[s] decreased
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disparities in clinical trials effectively, the FDA must promulgate binding
regulations requiring drug developers to increase diversity of clinical
trial participants, especially when the disease that the drug or
intervention targets disproportionately affects minority populations.
Part II of this Comment will briefly review the history of healthcare
disparities in minority populations and the medical and social
significance of these disparities. This Part will also examine how racial
disparities have played out in the context of the COVID-19 pandemic.
Part III will provide a brief overview of the FDA’s role in regulating
clinical trials to provide context for why the FDA is the correct entity to
address the lack of minority inclusion in clinical trials. Part IV will
review initiatives that the government has taken in the past to address
this issue. This Part will also provide examples of initiatives taken by
non-profit organizations, industry, and other private actors to increase
diversity in clinical trials. Finally, Part V will propose an FDA regulation
to increase diversity in clinical trials more effectively than the guidance
it has issued in the past. This Part will also provide suggested guidance
that can accompany the regulation to help members of the medical and
health care professions increase their access to diverse patient
populations. These suggestions will be similar to actions that non-profit
organizations and industry actors have taken in the past and consider
suggestions from experts in the field.
II. CAUSES AND SIGNIFICANCE OF RACIAL DISPARITIES IN HEALTHCARE
A. Racial Disparities in Healthcare and Clinical Trials
Healthcare disparities are systemic and consistent differences,
such as greater health risks and worse health outcomes, in
disadvantaged social groups such as racial and ethnic minorities.12 For
example, mortality rates from heart disease, stroke, and certain cancers
are much higher in Black populations; diabetes rates in Native
Americans and Latinx are 30 percent higher than White Americans; and
Black Americans’ life expectancy is nearly ten years less than White
ethnic diversity compared to last year’s approved drugs’ clinical trials, which included
69% White participants, 11% Black or African American, 10% Asian and 14%
Hispanic.”); Hala T. Borno et al., COVID-19 Disparities: An Urgent Call for Race Reporting
and Representation in Clinical Research, CONTEMP. CLINICAL TRIALS COMMC’NS (July 30,
2020), https://www.sciencedirect.com/science/article/pii/S2451865420301149 (“In
the United States, racial/ethnic minorities remain underrepresented in clinical research
with Black and Hispanic patients comprising approximately three and six percent of
clinical trial participants, respectively.”).
12 Racial and Ethnic Health Care Disparities, CTR. FOR MEDICARE ADVOC., https://medicareadvocacy.org/medicare-info/health-care-disparities/.
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Americans.13 There are a number of structural issues that prevent many
minority communities from having equal or even adequate access to
health care, including economic factors; linguistic, cultural, or religious
barriers; and geographic barriers.14
In addition to structural factors, some scholars indicate that
physicians’ implicit racial biases are another cause of racial healthcare
disparities.15 In 2005, the National Academy of Medicine (NAM) found
that even when controlling for factors such as insurance status, income,
age, comorbidities, and access to healthcare services, racial and ethnic
minorities still received lower-quality care than White patients.16 The
report concluded that some people are more likely to die from common
diseases like cancer and heart disease “simply because of their race or
ethnicity.”17 Physicians may be unaware that implicit biases negatively
impact the care they provide to minority patients. Still, experiments
have shown that physicians whose Implicit Association Test (IAT)
results showed anti-Black bias were less likely to prescribe pain
medications and specific (effective) treatments for heart disease to
Black patients compared to White patients.18 In conjunction with
structural factors, healthcare providers’ implicit biases dramatically
compromise the quality of care and health outcomes for racial and
ethnic minorities.

Wayne J. Riley, Health Disparities: Gaps in Access, Quality and Affordability of
Medical Care, 123 TRANSACTIONS AM. CLINICAL AND CLIMATOLOGICAL ASS’N 167, 168 (2012),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3540621/pdf/tacca123000167.pdf.
For detailed life expectancy data over the last century by race, see generally CTRS. FOR
DISEASE CONTROL & PREVENTION, LIFE EXPECTANCY AT BIRTH, AT AGE 65, AND AT AGE 75, BY SEX,
RACE, AND HISPANIC ORIGIN: UNITED STATES, SELECTED YEARS 1900–2016 (2017),
https://www.cdc.gov/nchs/data/hus/2017/015.pdf.
14 Racial and Ethnic Health Care Disparities, supra note 12. For a visualization of the
model of health disparities from the Institute of Medicine (IOM), see Riley, supra note
13 at 167–68.
15 Riley, supra note 13, at 169; Khiara M. Bridges, Implicit Bias and Racial Disparities
in Health Care, AM. BAR ASS’N, https://www.americanbar.org/groups/crsj/publications/
human_rights_magazine_home/the-state-of-healthcare-in-the-united-states/racial-disparities-in-health-care/ (last visited Oct. 24, 2021).
16 For example, Black patients have higher rates of limb amputation than White
patients; Black patients are typically discharged from hospitals after surgery earlier
than White patients, often when discharge is inappropriate; and Black patients are more
likely to be treated with antipsychotics for bipolar disorder compared to White patients,
despite evidence that these medications are ineffective and cause long-term negative
effects. Bridges, supra note 15.
17 Bridges, supra note 15.
18 Id.
13
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Minority communities also face widespread distrust of the medical
profession rooted in a history of mistreatment and abuse.19 Perhaps one
of the most well-known examples of this exploitation is the Tuskegee
Syphilis Study, where Black men with syphilis were “enrolled” in a
clinical study without their knowledge or consent.20 Because the study’s
purpose was to track the natural progression of untreated syphilis, the
men did not receive treatment for the disease even when penicillin
became a widely accepted cure.21 To this day, historical distrust is
reinforced by the fact that Black patients tend to have worse clinical
outcomes than White patients.22
Many of the barriers that racial and ethnic minorities face in
healthcare generally create obstacles to accessing and participating in
clinical trials. Because enrolling in a clinical trial is voluntary, patients
must be willing to participate.23 If minority patients do not trust their
doctors, it will be difficult to recruit minority patients even with the best
outreach programs.24 A survey study of men with prostate cancer found
that White men were far more willing to discuss clinical trials with their
doctors than Black men.25 The study found that the White men were less
likely to believe that they should be suspicious of the healthcare system
based on their race, while the Black men demonstrated greater groupbased medical suspicion.26 This is just one example of how increasing
trust in the medical system may reduce healthcare disparities and
improve equity in clinical research. Without representation in trials,
minority patients have no reason to trust experimental interventions or
newly approved treatments.27
19 This Comment will not expand upon the full history of unethical, inhumane, and
cruel abuses against Black bodies which remain in the collective consciousness of Black
Americans to this day. For a detailed history, see generally HARRIET A. WASHINGTON,
MEDICAL APARTHEID: THE DARK HISTORY OF MEDICAL EXPERIMENTATION ON BLACK AMERICANS
FROM COLONIAL TIMES TO THE PRESENT (2006).
20 The
Tuskegee Timeline, CTRS. FOR DISEASE CONTROL & PREVENTION,
https://www.cdc.gov/tuskegee/timeline.htm (last visited Oct. 24, 2021).
21 Id.
22 J. Corey Williams, Black Americans Don’t Trust our Healthcare System—Here’s
Why, HILL (Aug. 24, 2017), https://thehill.com/blogs/pundits-blog/healthcare/
347780-black-americans-dont-have-trust-in-our-healthcare-system.
23 U.S. FOOD & DRUG ADMIN., FDA ACTION PLAN TO ENHANCE THE COLLECTION AND
AVAILABILITY OF DEMOGRAPHIC SUBGROUP DATA 11 (2014) [hereinafter FDA ACTION PLAN],
https://www.fda.gov/media/89307/download.
24 Frederick et al., supra note 9.
25 Nicole Senft et al., Willingness to Discuss Clinical Trials Among Black vs White Men
With Prostate Cancer, 6 J. AM. MED. ASS’N ONCOLOGY 1773, 1774 (Nov. 2020), https://
jamanetwork.com/journals/jamaoncology/article-abstract/2770256.
26 Id. at 1773.
27 Frederick et al., supra note 9.
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In addition to the structural issues and physician biases discussed
above, the participant recruitment and referral processes inhibit
minority access to clinical trials.28 A paper from the Endocrine Society
noted that,
[P]harmaceutical companies and CROs [(Contract Research
Organizations)] only recruit physicians with a track record of
clinical research. Therefore, physicians with an interest in
clinical research, but with little experience, lack the
opportunities to participate in enough clinical trials to
maintain the infrastructure that they have worked so hard to
build. This results in minority physicians being underrepresented in clinical research and, as a consequence, their
patients, many of whom belong to ethnic minority groups, are
also under-represented.29
Minorities are largely underrepresented in drug and disease treatment
research even when a particular disease disproportionately affects a
minority group or groups. For example, one in five Americans
diagnosed with multiple myeloma is Black, yet in 2015, the FDA
approved a study drug for multiple myeloma treatment after a trial in
which only 1.8 percent of the participants were Black.30
B. Importance of Minority Representation in Clinical Trials
Clinical trials must include members of minority populations to
ensure that the results of those trials are relevant to those populations.
Many diseases disproportionately affect minority populations,31 and
clinical trials should include members of such populations to ensure the
interventions developed will benefit the populations who are most
affected by the disease.32 One of the most common justifications for
including minority populations in clinical trials is genetics. Genetics can
28 See generally ENDOCRINE SOCIETY, INCREASING MINORITY PARTICIPATION IN CLINICAL
RESEARCH (2007), https://www.endocrine.org/~/media/endosociety/files/advocacyand-outreach/important-documents/increasingminorityparticipationinclinicalresearch.pdf?la=en.
29 Id. at 5–6 (emphasis added).
30 Balt. Sun Editorial Bd., Editorial, African Americans and Hispanics Must Be a Part
of Vaccine Trials, and It’s Up To Doctors and Researchers to Earn Their Trust, BALT. SUN
(Sept. 18, 2020, 5:53 AM), https://www.baltimoresun.com/opinion/editorial/bs-ed09-covid-vaccine-african-americans-hispanics-20200918-yxea5t5qwng5njr5lhcpykaobm-story.html.
31 See supra Section II.A.
32 FDA ACTION PLAN, supra note 23, at 11 (“FDA fully supports efforts to encourage
participation of underrepresented ethnic and racial subgroups participating in clinical
trials in applications for all FDA-regulated medical products, so that knowledge about
the safety and effectiveness of these products is informative to patients who may use the
products.”) (emphasis added).
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affect how our bodies metabolize drugs and medications.33 This is
particularly true for vaccines, which work by manipulating the immune
system.34 Further, some diseases manifest differently depending upon
a person’s race or ethnicity.35
Because racial categories are social constructs rather than
biological facts, membership in a self-defined racial group does not
define one’s genetic makeup. In fact, looking at genetics alone, scientists
cannot distinguish between races.36 Even when certain genetic features
can be grouped and associated with “quasi-distinct” categories, these
categories do not align with socially-constructed racial groups.37 For
example, there could be more genetic similarities between a racially
Asian individual and a racially White individual than between two
racially Black individuals.38 And while certain genes can impact rates of
disease and pharmaceutical metabolism, these genes “do not align
neatly with reductive racial categories often employed to represent
geographic origin.”39 Consequently, making health decisions based
upon race can lead to more mistakes and thus worse health outcomes.40
Nevertheless, there is sometimes a correlation between selfidentified racial groups and genetic characteristics, given that racial
categories often are based on the geographic location of a person’s
ancestors.
For example, from observational studies and
pharmacogenetics (the study of how an individual’s genetics affect his
or her drug response), we know that responses to medications can vary
Frederick et al., supra note 9.
Frederick et al., supra note 9; see also Daniel S. Streetman, Pharmacogenomics and
Race: Can Heritage Affect Drug Disposition?, WOLTERS KLUWER (Apr. 18, 2017), https://
www.wolterskluwer.com/en/expert-insights/pharmacogenomics-and-race-can-heritage-affect-drug-disposition (“[W]hen it comes to how our bodies metabolize and react
to medications, we should not all be viewed as the same.”).
35 Balt. Sun Editorial Bd., supra note 30.
36 Selin Ege Yalcindag, There is No Biological Meaning for ‘Race,’ ILL. SCI. COUNCIL (Sept.
7, 2020), https://www.illinoisscience.org/2020/09/there-is-no-biological-meaningfor-race/.
37 Id.
38 Id.; Jennifer Tsai, What Role Should Race Play in Medicine?, SCI. AM. (Sept. 12, 2018),
https://blogs.scientificamerican.com/voices/what-role-should-race-play-in-medicine/
(“Research demonstrates that genetic differences are higher within racial groups than
between racial groups—that two black patients sitting in the waiting room will have less
genetic overlap with each other than with their white, Asian, or Hispanic neighbors.”).
39 Tsai, supra note 38.
40 See Scientists Call for the Removal of Race in Genetics Research, WHYY (Feb. 18,
2016), https://whyy.org/segments/scientists-call-for-the-removal-of-race-in-geneticsresearch/ (“[B]ecause of the myth that sickle cell is a black disease, or cystic fibrosis is a
white disease, white patients may be under diagnosed for sickle cell and other
hemoglobin diseases, and black patients have been under diagnosed for cystic
fibrosis.”).
33
34
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among individuals of different races or ethnicities.41 A 2015 study
concluded that about 20 percent of newly approved drugs have different
responses based on the user’s race or ethnicity.42 For example,
individuals of African or Mediterranean descent more commonly have a
G6PD deficiency (a type of genetic abnormality) that places them at
higher risk of hemolysis when exposed to certain medications such as
antimalarial medications and sulfa drugs.43 While the reasons for these
varying responses are not entirely understood, some are attributed to
specific genetic differences.44 For many race-specific disposition
differences, however, a specific genetic difference is not known.45
Aside from genetics, race is also relevant because of social
determinants of health.46
Differences in access to healthcare,
employment, and clean, safe living conditions can lead to data that
reflect racial differences in health outcomes.47 These disparities “are
engineered from a great number of social inequalities that
disproportionately impact certain groups.”48 Negative healthcare
outcomes are not a result of racial differences—rather, the healthcare
disparities themselves are forms of “racial inequities driven by
injustice.”49 With so many social factors at play, conclusions cannot
always be accurately drawn about racial or genetic predispositions to
health outcomes.50 In a perfect world, doctors would consider their
patients’ social conditions rather than race, especially when caring for
minority populations.51
Some scholars argue that “racial categories are weak proxies for
genetic diversity [that] need to be phased out.”52 Jennifer Tsai, an
Streetman, supra note 34.
Id.
43 Id.
44 Id.
45 Id.
46 See infra Section II.C.i. for a more in-depth discussion of social determinants of
health.
47 Yalcindag, supra note 36; Tsai, supra note 38 (“While African-American women
fight to endure appalling rates of maternal mortality, white men are most likely to die
from opioid overdose. These are not biological predispositions.”).
48 Tsai, supra note 38.
49 Id.
50 Yalcindag, supra note 36.
51 Scientists Call for the Removal of Race in Genetics Research, supra note 40.
52 Megan Gannon, Race is a Social Construct, Scientists Argue, SCI. AM. (Feb. 5, 2016),
https://www.scientificamerican.com/article/race-is-a-social-construct-scientists-argue/ (“[M]odern genetics research is operating in a paradox, which is that race is
understood to be a useful tool to elucidate human genetic diversity, but on the other
hand, race is also understood to be a poorly defined marker of that diversity and an
imprecise proxy for the relationship between ancestry and genetics.”).
41
42
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emergency physician, disagrees, arguing, “[r]ather than a
risk factor that predicts disease or disability because of genetic
susceptibility, race is better conceptualized as a risk marker—of
vulnerability, bias or systemic disadvantage.”53 She argues that because
of the ubiquity of racial disparities in healthcare, we should not be
asking whether or not to use race in medicine; rather, we should
consider “how [to] use race well.”54 When used effectively, race should
not be used as a proxy for genetics—except where racially-correlated
genetic differences are known—or as an independent risk factor that is
itself a cause of worse health outcomes; instead, race should be used as
an indicator of potential risks caused by external social determinants.55
Social determinants affect responses to drugs or vaccines and
should be considered during the clinical trial process by enrolling
diverse trial participants. Differences in people’s underlying medical
conditions, for example, can affect vaccine effectiveness.56
In
individuals with preexisting conditions such as diabetes or HIV
infection, both of which affect Black Americans at a higher rate than
White Americans, vaccines have proven to be less effective.57
Behavioral factors, such as smoking, alcohol consumption, exercise,
sleep, and psychological stress, and nutritional factors, such as body
mass index and nutritional status, also contribute to variations in
vaccine responses—both the protection’s efficacy and duration.58
Because vaccine effectiveness can be impacted by differences in
underlying conditions and can vary in groups of people not included or
well-represented in clinical trials, vaccines that the FDA approves for
emergency use must continue to be studied to determine their
effectiveness under real-world conditions.59 Including racially diverse
participants in clinical trials would better ensure that vaccines are safe
and effective for real-world populations at the time of approval, rather
than relying upon post-approval studies that effectively force
Tsai, supra note 38.
Id.
55 Id.
56 Ensuring COVID-19 Vaccines Work, CTRS. FOR DISEASE CONTROL & PREVENTION (Dec.
13, 2020), https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness.html.
57 Ananya Mandal, Vaccine Effectiveness, NEWS MED. (June 5, 2019), https://
www.news-medical.net/health/Vaccine-Effectiveness.aspx.
58 For example, both adults and children who are infected with HIV show lower
responses to various vaccines, including tetanus and measles, and patients with diabetes
mellitus are associated with lower responses to Hepatitis B vaccination. Petra
Zimmermann & Nigel Curtis, Factors That Influence the Immune Response to Vaccination,
32 AM. SOC’Y FOR MICROBIOLOGY, Mar. 13, 2019, https://cmr.asm.org/content/32/
2/e00084-18.full.
59 Ensuring COVID-19 Vaccines Work, supra note 56.
53
54
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disadvantaged populations to participate in a post-approval “clinical
trial” without their knowledge or consent.
C. Racial Diversity in COVID-19 Clinical Trials
While a lack of diversity and inclusion in clinical trials is nothing
new, the COVID-19 pandemic highlights how much more work still
needs to be done. Because COVID-19 disproportionately affects
minority communities, treatment and vaccine clinical trials need to
include diverse populations to ensure the interventions developed will
benefit the populations who are most affected by the disease. Vaccine
trials proceeded quickly, and the lack of diversity illustrates the urgency
of the ongoing challenge to improve inclusion in clinical trials.
1. Why COVID-19 Disproportionately Affects Minority
Populations
Healthcare disparities and structural and societal factors, such as
living and working conditions, reinforce these disparities, placing
minority communities at a disadvantage during the COVID-19
pandemic.60 The disproportionate impact that the pandemic has on
racial and ethnic minority groups highlights relevant issues in medical,
social, economic, and political contexts that have existed since long
before the pandemic.61
Minority groups that are disproportionately affected by chronic
medical conditions and lower access to health care have worse COVID19 infection and mortality rates.62 In cities like New York and San
Francisco, Black and Hispanic Americans face higher rates of mortality,
infection, and death from COVID-19.63 Compared to White Americans,
Black Americans are disproportionately burdened by chronic
preexisting conditions such as diabetes mellitus, hypertension, and
obesity, all of which increase a patient’s risk of severe COVID-19
infection and mortality; this longstanding disparity directly contributes

60 CDC data shows that 20.1 percent of COVID-19 cases were Black Americans,
though they make up only 13.4 percent of the population. Similarly, 33.5 percent of
cases were Hispanic individuals, who make up only 18.5 percent of the population.
Borno et al., supra note 11.
61 Wilder, supra note 3, at 709–10, refers to the combination of factors discussed in
Tai, et al., infra note 62, as a second pandemic: “The pandemic of social determinants”
(“Our unwillingness to confront the issue of racism in healthcare head-on will continue
to impede our ability to achieve true health equity.”).
62 Don Bambino Geno Tai et al., The Disproportionate Impact of COVID-19 on Racial
and Ethnic Minorities in the United States, 72 CLINICAL INFECTIOUS DISEASES 705 (2021),
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa815/5860249.
63 Borno et al., supra note 11, at 1.
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to disproportionately high infection rates and negative outcomes for
Black Americans with COVID-19.64 Chronic preexisting medical
conditions are further exacerbated by less access to quality healthcare.65
Black Americans, Hispanic Americans, and Native Americans have
higher uninsured rates compared to White Americans (12 percent, 19
percent, and 22 percent, respectively, compared to 8 percent), in
addition to living in areas with lower quality medical care.66 If infected
with COVID-19, these minority individuals will likely receive lowerquality care, which could lead to worse health outcomes.
Economic factors also contribute to the disparities in preexisting
medical conditions and healthcare access. Compared to only 9 percent
for Whites, the pre-COVID-19 poverty rates for Black Americans,
Hispanic Americans, and Native Americans were 22 percent, 19 percent,
and 24 percent, respectively.67 Lower-income individuals lack the
financial security to make necessary “healthful decisions” during the
pandemic.68 In New York City, 75 percent of frontline “essential”
workers are people of color who were unable to work from home, many
of whom even continued to use public transportation as their only
means of getting to work.69 Minority communities also frequently have
higher housing density and are more likely to live with multiple
generations of family members, circumstances that make social
distancing much more difficult, if not impossible.70 Other social
determinants, such as language barriers and health illiteracy, prevent
essential health information about the pandemic from being
communicated to some minority populations.71 As a result, the risk of
COVID-19 spreading through these communities is higher than other
communities because of the “relative lack of credible COVID-19
information.”72

Tai et al., supra note 62, at 705.
Borno et al., supra note 11, at 1.
66 Tai et al., supra note 62, 705–06.
67 Id. at 706.
68 Id.
69 Id.
70 Id.
71 Id.
72 Tai et al., supra note 62, at 706. For how the factors described in this section are
relevant to the efficacy of COVID-19 vaccines, see infra Section II.B. beginning with note
46.
64
65
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2. COVID-19 Clinical Trials
Researchers and drug developers have historically failed at
achieving inclusiveness in clinical trials, and the clinical trials for COVID19 treatments and the development of a COVID-19 vaccine are no
different.73 So far, COVID-19 treatment trials have not included
sufficiently diverse populations, despite the fact that Black and Latinx
communities have been disproportionately affected by the disease.74 A
study conducted by researchers at the University of California San
Francisco assessed the race representation in COVID-19 treatment
studies through July 10, 2020.75 The results found that race and
ethnicity were inconsistently collected and reported and that “Black
patients were consistently underrepresented relative to their disease
burden.”76
In one New York-based retrospective study of
Hydroxychloroquine in COVID-19 patients, Black patients made up only
11 percent of the study population—meanwhile, Black Americans made
up 30.5 percent of New York’s COVID-19 cases.77 Interestingly, in the
same study, Hispanic patients were vastly overrepresented—51
percent of the study population, but 32.7 percent of all cases—and
race/ethnicity data was missing for 23.2 percent of the study
participants.78 Black and Hispanic patients were also underrepresented
compared to the relative affected population in studies in Boston and
Minneapolis.79
Knowing the history of clinical research with minority
communities, scientists realize their obligation to create a vaccine that
works for the diverse populations who will need it. One of the leading
scientists on the Pfizer vaccine study understands the importance of
diversity in understanding how a drug or vaccine will work in the
general population:
A question we always ask ourselves, when we do clinical trials,
are how generalizable will results be to people who suffer
from the disease? . . . If you did a study in a majority-White
population with very little Black individuals, when we do get
results from the study, it will always be a question: Does it

73
74
75
76
77
78
79

Balt. Sun Editorial Bd., supra note 30.
See generally Borno et al., supra note 11.
Id. at 1.
Id. at 3.
Id. at 2.
Id.
Id.
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work the same in Black [people] as compared to others? And
that’s even more so for covid.80
Yet by the end of August 2020, when Moderna’s and Pfizer’s
vaccine trials had enrolled more than half of the target study population,
just below one-fifth of the participants were Black or Hispanic.81 In early
October 2020, Moderna had still not recruited sufficient Black, Latinx,
or Native American participants, leading the company to slow trial
enrollment to prioritize minority recruitment.82 Investigators working
on the clinical trial reported that while minority recruitment lagged,
trial quotas were quickly filled by “overwhelming interest in
participation from [W]hite volunteers.”83 And in an online registry used
for expressing interest in vaccine trials as of late August, Black and
Hispanic people made up only 10–11 percent of volunteers.84
While current enrollment does not even mirror the demographic
breakdown of the U.S. population as a whole (about 33 percent Black,
Hispanic, and Native American), many experts argue that this target is
too low: instead, enrollment efforts should “reflect the disproportionate
burden of disease.”85 As evidenced by current enrollment, these goals
would be difficult to achieve, largely because of minority populations’
distrust of the medical community caused by a history of being subjects
for experimentation without knowledge or consent.86 The scientific and
medical communities owe it to minority populations to address these
fears. Only by addressing these fears can we hope to lessen the death
80 Carolyn Y. Johnson, Large U.S. COVID-19 Vaccine Trials are Halfway Enrolled, but
Lag on Participant Diversity, WASH. POST (Aug. 27, 2020), https://www.washingtonpost.com/health/2020/08/27/large-us-covid-19-vaccine-trials-are-halfway-enrolled-lag-participant-diversity/.
81 Id. (“Creating vaccine trials that, at minimum, mirror the racial and ethnic
breakdown of the American population, which is about one-third total Black, Hispanic
and Native American, has been a major focus — a necessity to make sure any vaccine
works for everyone and is broadly accepted.”); Balt. Sun Editorial Bd., supra note 30.
82 Justine Coleman, Moderna Vaccine Trials Slowed by Insufficient Minority
Participants: Report, HILL (Oct. 6, 2020), https://thehill.com/policy/healthcare/
519807-moderna-vaccine-trials-slowed-by-insufficient-minority-participants-report.
83 Id.
84 Johnson, supra note 80 (quoting James Kublin, executive director of the federal
HIV Vaccine Trials Network, which is currently being repurposed to test coronavirus
vaccines (“We are working a bit uphill . . . to get the studies representing the diversity
[of the U.S.] — and that goes into the historical legacy of not just discrimination, but of
outright unethical medical practices . . . .”) (alteration in original)).
85 Id. (quoting Hala Borno, a medical oncologist at the University of California at San
Francisco who studied coronavirus clinical trials that disclosed racial data and found
that Blacks were underrepresented (“[T]he way that scientific research goes, is you need
a sufficient sample to power your analysis, to determine there is a real difference for
that population. You need to oversample racial and ethnic minorities.”)).
86 Coleman, supra note 82.
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toll of COVID-19 in hard-hit communities.87 We must increase inclusion
in clinical research, especially trials related to COVID-19, to address
disparities in health outcomes.88 The COVID-19 pandemic has given
medical and healthcare professionals a more powerful voice in society.
These professionals now have the opportunity to unravel the old
system, filled with social inequities, to design a “more equitable system
that promotes health for all Americans irrespective of social or
economic background.”89
III. THE ROLE OF THE FDA IN REGULATING CLINICAL TRIALS
The FDA is the federal agency responsible for regulating clinical
trials. The FDA derives much of its statutory authority from the Food,
Drug, and Cosmetics Act, which states that missions of the FDA include
“promot[ing] the public health by promptly and efficiently reviewing
clinical research,” and “ensuring that . . . human . . . drugs are safe and
effective.”90 These missions should be carried out “in consultation with
experts in science, medicine, and public health, and in cooperation with
consumers, users, [and] manufacturers . . . of regulated products.”91
Further, the FDA’s programs and policies should encourage
collaboration with “the National Institutes of Health, and other sciencebased Federal agencies, to enhance the scientific and technical expertise
available . . . with respect to the development, clinical investigation,
[and] evaluation . . . of emerging medical therapies.”92 The FDA has
promulgated numerous regulations to execute its statutory missions
relating to clinical trials.93 For example, one way the FDA regulates
clinical trials is by requiring sponsors to submit an Investigational New
Drug Application (IND) to the FDA before conducting a clinical trial.94
New, untested drugs typically go through three phases of
investigation, referred to as Phases I, II, and III.95 Phase I investigations
are closely monitored, as they primarily focus on determining the
maximum dose of a drug that can be administered safely without
causing severe side effects.96 Phase II investigations study the
effectiveness of the new intervention and also further evaluate risks and
87
88
89
90
91
92
93
94
95
96

Balt. Sun Editorial Bd., supra note 30.
See Borno et al., supra note 11.
Tai et al., supra note 62, at 707.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 393(b)(1), (b)(2)(b) (2020).
21 U.S.C. § 393(b)(4).
21 U.S.C. § 393(c).
See generally 21 C.F.R. §§ 312.1–312.320 (2019).
21 C.F.R. § 312.20.
§ 312.21.
See id.
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short-term side effects associated with the drug.97
Phase III
investigations collect “additional information about effectiveness and
safety that is needed to evaluate the overall benefit-risk relationship of
the drug and to provide an adequate basis for physician labeling.”98 As
a trial moves through the phases, the number of subjects included in the
trial increases from approximately twenty to several thousand.99
The FDA has the power to place a clinical hold to suspend an
ongoing investigation,100 and utilizes this power to enforce compliance
with regulations related to clinical trials. In existing regulations, the
FDA lists a number of specified grounds for issuing a clinical hold at each
phase of the trial process.101 For example, the FDA may place Phase II
or III studies on hold if the “plan or protocol for the investigation is
clearly deficient in design to meet its stated objectives.”102 If the FDA
identifies a study deficiency, it will “attempt to discuss and satisfactorily
resolve the matter with the sponsor before issuing the clinical hold
order.”103 If a hold order is issued, the trial may not resume until the
FDA lifts the order because the sponsor has either (1) corrected the
cited deficiency, or (2) “otherwise satisfie[d] the agency that the
investigation(s) can proceed.”104
IV. PAST AND CURRENT EFFORTS TO INCREASE RACIAL DIVERSITY IN CLINICAL
TRIALS
A. Government Initiatives
1. NIH Revitalization Act of 1993
The NIH is a federal agency within the Department of Health and
Human Services responsible for medical research.105 The NIH conducts
biomedical research projects and funds research projects conducted by
public and private entities.106 The NIH Revitalization Act of 1993
required the NIH to create a policy that would increase the inclusion of

Id.
Id.
99 Id.
100 § 312.42(a).
101 § 312.42(b).
102 Id.
103 § 312.42(c).
104 § 312.42(e).
105 Who We Are, NAT’L INSTS. HEALTH, https://www.nih.gov/about-nih/who-we-are
(last visited Oct. 24, 2021).
106 Mission and Goals, NAT’L INSTS. HEALTH (July 27, 2017), https://www.nih.gov/
about-nih/what-we-do/mission-goals.
97
98
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women and minorities in clinical research.107 The Act states that “[t]he
Director of NIH . . . shall conduct or support outreach programs for the
recruitment of . . . members of minority groups as subjects in projects of
clinical research,” and that “the costs of such inclusion in the trial is not
a permissible consideration in determining whether such inclusion is
inappropriate.”108 The Act also provides exceptions to the requirement
for inclusion of minorities in clinical trials when “there is substantial
scientific data demonstrating that there is no significant difference
between” the effects of the intervention on minority groups and other
trial subjects.109
Following this directive, the NIH issued a policy that requires,
[M]inority groups and their subpopulations [to] be included
in all NIH-funded clinical research, unless a clear and
compelling rationale and justification establishes to the
satisfaction of the relevant Institute/Center Director that
inclusion is inappropriate with respect to the health of the
subjects or the purpose of the research . . . . The inclusion of
. . . members of minority groups and their subpopulations
must be addressed in developing a research design or contract
proposal appropriate to the scientific objectives of the
study/contract.110
Mirroring the statute, the policy states that “[c]ost is not an acceptable
reason for exclusion except when the study would duplicate data from
other sources.”111 Policy exceptions may be permitted based on
“compelling rationale and justification” at the NIH Director’s
discretion.112 Evidence showing whether or not “race/ethnicity
differences in the intervention effect are to be expected” must be
reviewed during the proposal of an NIH-defined Phase III clinical trial.113

107 Nat’l Insts. Health, NIH Policy and Guidelines on the Inclusion of Women and
Minorities as Subjects in Clinical Research, NIH GRANTS & FUNDING (Dec. 6, 2017),
https://grants.nih.gov/policy/inclusion/women-and-minorities/guidelines.htm.
An
amendment to the policy was made on November 28, 2017. The only significant change
to the policy is the requirement that sex/gender, race, and/or ethnicity analysis are
submitted to clinicaltrials.gov for applicable NIH-defined Phase III clinical trials.
Because this Comment focuses on minority communities, efforts to include women in
clinical research will not be discussed, though it is worth noting that efforts to increase
gender-based diversity in clinical trials have been largely successful.
108 National Institutes of Health Revitalization Act of 1993, Pub. L. No. 103–43,
§ 492B, 107 Stat. 122, 134 (1993).
109 Id. at 135.
110 Nat’l Insts. Health, supra note 107.
111 Id.
112 Id.
113 Id.
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If data supports “the existence of significant differences,” the Phase III
trial design must accommodate this.114
2. FDA Guidance Documents & Drug Trials Snapshots
The FDA has undertaken various initiatives to increase diversity in
clinical trial participants and standardize the collection and reporting of
race and ethnicity data.115 Many of these initiatives have focused on
broadening eligibility criteria, including “characteristics such as age,
sex, medical history, current health status, presence or absence of
certain genotypes, blood pressure or other physiologic parameter, and
absence of certain diseases,” to promote enrollment of participants that
better reflect the population.116
In 2014, the FDA released the “FDA Action Plan to Enhance the
Collection and Availability of Demographic Subgroup Data” (“Action
Plan”).117 The Action Plan was published in response to Section 907 of
the Food and Drug Administration Safety and Innovation Act of 2012
(FDASIA), which directed the FDA to provide Congress information
regarding demographic subgroup participation in clinical trials and the
availability of safety and efficacy data for specific subgroups.118 Section
907 also mandated the FDA to issue an action plan making
recommendations to improve,
the completeness and quality of analyses of data on
demographic subgroups in summaries of product safety and
effectiveness data and in labeling; . . . the inclusion of such
data, or the lack of availability of such data in labeling; . . .
[and] the public availability of such data to patients, health
care providers, and researchers.119
The Action Plan acknowledged that certain subgroups, including
Blacks, Hispanics, and U.S. Asians, are less likely to participate in clinical
trials compared to the population as a whole, and further acknowledged
that “[p]articipation in clinical trials is voluntary, so in order to have
Id.
See, e.g., U.S. FOOD & DRUG ADMIN., COLLECTION OF RACE AND ETHNICITY DATA IN CLINICAL
TRIALS: GUIDANCE FOR INDUSTRY AND FOOD AND DRUG ADMINISTRATION STAFF 1 (2016)
[hereinafter 2016 GUIDANCE DOCUMENT]; see generally Clinical Trials Guidance Documents,
U.S. FOOD & DRUG ADMIN., https://www.fda.gov/regulatory-information/search-fdaguidance-documents/clinical-trials-guidance-documents (last visited July 29, 2021).
116 U.S. FOOD & DRUG ADMIN., ENHANCING THE DIVERSITY OF CLINICAL TRIAL POPULATIONS —
ELIGIBILITY CRITERIA, ENROLLMENT PRACTICES, AND TRIAL DESIGNS: GUIDANCE FOR INDUSTRY 2 n.2
(2020) [hereinafter 2020 GUIDANCE DOCUMENT].
117 FDA ACTION PLAN, supra note 23.
118 See Food and Drug Administration Safety and Innovation Act, Pub. L. No. 112–144,
§ 907, 126 Stat. 993, 1092–93 (2012).
119 Id. at 1093–94.
114
115
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clinical trials with diversity among participants, a diverse population of
people has to be willing to participate.”120
One priority of this Action Plan was to encourage greater subgroup
participation in clinical trials by identifying barriers to enrollment and
implementing strategies to work around those barriers.121 The Action
Plan noted several barriers to participating, including a shortage of
investigators who have access to patients who belong to demographic
subgroups; “patients and families with negative attitudes about medical
research and concerns about risk”; patient inconvenience, such as
transportation requirements and geographic location; and insurance or
socioeconomic status affecting access to trials and healthcare.122 The
Action Plan stated that the “FDA fully supports efforts to encourage
participation of underrepresented ethnic and racial subgroups
participating in clinical trials . . . so that knowledge about the safety and
effectiveness of these products is informative to patients who may use
the products.”123
To address these participation barriers, the Action Plan contained
several “Action Items,” such as acknowledging that the issue “is not one
of race and ethnicity alone” and introducing a plan to work with experts
to better understand contemporary barriers to participation.124 The
Action Plan also proposed increasing effective communication with
demographic subgroups about clinical trial participation, including
distributing information in both English and Spanish, as well as
establishing a “joint working group” that would “explore educational
tools and outreach mechanisms to more broadly engage subgroups that
consistently have low participation rates in clinical trials” and increase
awareness about the value of participating in clinical trials.125 Even with
these Action Items, the Action Plan acknowledged that increasing
subgroup participation in clinical trials is a complex issue that requires
coordination with the NIH, advocacy groups, and industry and increased
focus on community-based research.126
In 2015, the FDA’s Center for Drug Evaluation and Research
(CDER) began publishing Drug Trials Snapshots to make available to
consumers and healthcare providers demographic information about

FDA ACTION PLAN, supra note 23, at 11.
Id.
122 Id. at 11–12.
123 Id. at 11.
124 Id. at 12.
125 Id. at 13–14.
126 FDA ACTION PLAN, supra note 23, at 13. See infra Section IV.B. for more information
about industry initiatives to increase minority participation in clinical trials.
120
121
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who participated in the clinical trials for newly approved drugs.127 Each
Snapshot indicates any differences in efficacy or side effects based on
sex, age, or race, and provides a breakdown of the percentages of
participants based on sex, age, and race.128 At the end of each year, the
FDA releases the “Drug Trials Snapshots Summary Report,” which
further breaks down demographic subgroups of all participants in trials
for approved drugs.129 In the annual report, demographic subgroups are
broken down into White, Black or African American, Asian, and
Hispanic.130 For some drugs, certain demographic information is not
reported.131
The Snapshots’ purpose is to enhance transparency and “promote
dialogue on the appropriate representation of different subgroups in
clinical trials.”132 While a thoughtful initiative, the Snapshots have two
major limitations: (1) conclusions regarding differences in safety and
efficacy among different demographic groups “cannot always be made,”
and by looking at a few different snapshots, it appears that the inability
to form conclusions happens often; and (2) Snapshots are posted within
thirty days of drug approval and are not updated to reflect new
information as it may become available.133 Because the FDA typically
approves drugs following Phase III,134 the post-approval period—
sometimes called Phase IV or a “post marketing surveillance” study—
often produces additional safety or efficacy data that was not detected
prior to FDA approval.135 The “true safety profile” of a drug often is not
fully developed until the drug has been made available on the market.136
Because new information is not added to the Snapshot profile, a
consumer or healthcare provider may not be considering the complete
safety or efficacy information available for a certain drug when looking
at Snapshot data.
In a complement to the Drug Trials Snapshots initiative, the FDA
issued a guidance document in 2016 to establish a “standardized
Drug Trials Snapshots, U.S. FOOD & DRUG ADMIN. (Apr. 9, 2021) [hereinafter
Snapshots], https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trialssnapshots.
128 See, e.g., Drug Trials Snapshots: ACCRUFER, U.S. FOOD & DRUG ADMIN. (Aug. 15,
2019), https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-accrufer.
129 See U.S. FOOD & DRUG ADMIN., 2020 DRUG TRIALS SNAPSHOTS SUMMARY REPORT 2 (2021).
130 Id. at 3.
131 Id.
132 Id. at 2.
133 Snapshots, supra note 127.
134 See supra Part III.
135 Viraj Suvarna, Phase IV of Drug Development, 1 PERSPS. CLINICAL RSCH. 57, 57 (2010).
136 Id.
127
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approach for collecting and reporting race and ethnicity data in
submissions for clinical trials,” because the use of standardized methods
and terminology ensures that data is collected uniformly and
consistently.137 Per FDA regulations, trial sponsors are expected to
“enroll participants who reflect the characteristics of clinically relevant
populations with regard to age, sex, race, and ethnicity.”138 The
guidance document provides that,
A plan to address inclusion of clinically relevant
subpopulations should be submitted . . . to the Agency at the
earliest phase of development and, for drugs and biologics, no
later than the end of the phase 2 meeting. Inadequate
participation and/or data analyses from clinically relevant
subpopulations can lead to insufficient information pertaining
to medical product safety and effectiveness for product
labeling.139
The most recent guidance document, titled “Enhancing the
Diversity of Clinical Trial Populations—Eligibility Criteria, Enrollment
Practices, and Trial Designs: Guidance for Industry,” was introduced for
public comment in June 2019 and finalized in November 2020.140 This
guidance document was issued to comply with Section 610 of the FDA
Reauthorization Act of 2017 (FDARA), which required the FDA to
“convene a public meeting to discuss clinical trial inclusion and
exclusion criteria to inform the guidance” and issue a report on the
matter.141 This guidance document focuses primarily on how sponsors
can increase underrepresented populations’ enrollment in clinical trials
using inclusive trial practices.142 It also discusses “improving trial
recruitment so that the participants enrolled in trials will better reflect
the population most likely to use the drug.”143
Obstacles to enrolling in clinical trials include the burden of
frequent visits to specific sites, financial costs from traveling or missing
work, and distrust of clinical research among certain populations.144
The FDA suggests sponsors can improve the diversity of study
2016 GUIDANCE DOCUMENT, supra note 115 at 1.
2020 GUIDANCE DOCUMENT, supra note 116, at 5; see 21 C.F.R. §§ 314.50(d)(v),
(vi)(a) (Safety and efficacy data in NDAs “must be presented by . . . racial subgroups and
must identify any modifications of dose or dose interval needed for specific
subgroups.”).
139 2016 GUIDANCE DOCUMENT, supra note 137, at 3.
140 2020 GUIDANCE DOCUMENT, supra note 116.
141 FDA Reauthorization Act of 2017, Pub. L. No. 115–52, § 610, 131 Stat. 1005, 1051
(2017).
142 See generally 2020 GUIDANCE DOCUMENT, supra note 116, at 4–7.
143 Id. at 3.
144 See supra Section II.A.
137
138
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participants by considering these logistical barriers when designing the
clinical trial and provides a number of potential approaches.145 For
example, the section titled “Make Trial Participation Less Burdensome
for Participants” suggests that trial sponsors should take note of
recruitment challenges that the study’s planned visit schedule may
cause and consider reducing the number of visits, increasing flexibility
in visit windows when possible, using technology to replace in-person
visits, or providing financial reimbursements for travel or lodging
expenses.146 Another section titled “Adopt Enrollment and Retention
Practices That Enhance Inclusiveness” urges trial sponsors to work with
communities to better understand why participants may be reluctant to
enroll in a clinical trial to better address participants’ needs and to
involve the participants, their families, and patient advocates in the trial
design process; to select trial sites located in areas with higher
concentrations of minority populations; to consider diversity when
selecting health care providers; and to make further efforts to increase
diversity through public outreach and education within the industry, in
partnership with patient advocacy groups and medical associations.147
It is worth noting that while guidance documents represent the
“current thinking” on a topic, the guidance is “not binding on the FDA or
the public” and creates no legally enforceable responsibilities.148
Despite these various FDA initiatives, diversity in clinical trials is not
significantly improving.149
B. Non-Profit Organizations, Industry, and Other Private Actors
Despite the lack of binding diversity requirements from the FDA,
private actors often implement their own plans to increase diversity in
their clinical trials, though the success of these initiatives is sometimes
unclear.
2020 GUIDANCE DOCUMENT, supra note 116, at 9.
Id. at 9–10.
147 Id. at 10.
148 2016 GUIDANCE DOCUMENT, supra note 137, at 2 (“FDA’s guidance documents . . . do
not establish legally enforceable responsibilities. Instead, guidances describe the
Agency’s current thinking on a topic and should be viewed only as recommendations,
unless specific regulatory or statutory requirements are cited. The use of the word
should in Agency guidances means that something is suggested or recommended, but
not required.”).
149 Barba, supra note 11; Luther T. Clark et al., Increasing Diversity in Clinical Trials:
Overcoming Critical Barriers, 44 CURRENT PROBLEMS IN CARDIOLOGY 148, 150 (2019)
(“[D]espite major efforts, including those from the US FDA and the Revitalization Act of
1993, which required that clinical trials funded by the National Institutes of Health
include women and minority participants, diversity in clinical trials has not substantially
improved.”).
145
146

PERLSTEIN (DO NOT DELETE)

566

11/12/21 3:47 PM

SETON HALL LAW REVIEW

[Vol. 52:545

For example, the Center for Information and Study on Clinical
Research Participation (CISCRP) is “dedicated to educating and
informing the public, patients, medical/research communities, the
media, and policy makers about clinical research and the role each party
plays in the process.”150 CISCRP offers a number of services and
programs to help consumers find trials that are relevant to their specific
needs and learn more about clinical trials by providing “plain language
translation” of research documents.151 CISCRP also focuses on
community engagement by increasing awareness about clinical trials
through media campaigns and hosting educational events in diverse
communities to further enable individuals to make informed decisions
about participation in clinical trials.152 Perhaps most importantly,
CISCRP collects information about patient perceptions and experiences
with clinical research.153 Listening to patients and understanding their
concerns allows for the development of new initiatives which are more
likely to achieve the goal of increased diversity efficiently and
effectively.
Pharmaceutical companies, as sponsors of clinical trials, are also
taking steps to increase minority participation. Biogen, for example, is
undertaking various initiatives to increase diversity in their clinical
trials by providing “diversity and cultural sensitivity training” for its
clinical trial sites; focusing on opening its trials at sites that serve a
diverse patient population and underserved communities; forming a
Community Advisory Board to help develop educational materials about
clinical trials and develop new initiatives for working with underserved
communities; including participant race and ethnicity goals in the trial
design which reflect the patient population affected by a specific
disease; and collaborating on a study with the Tufts Center for the Study
of Drug Development (Tufts CSDD) to learn more from patients,
healthcare experts, and community members about the obstacles
patients face in clinical trial participation.154 These initiatives reflect
Biogen’s commitment to “putting the weight of our business, our
employees, and our collaboration partners to help close the disparity
gap in clinical trials and access to healthcare.”155
About Us, CISCRP, https://www.ciscrp.org/about-us/ (last visited Sept. 12, 2021).
Services and Programs, CISCRP, https://www.ciscrp.org/services/ (last visited
Sept. 12, 2021).
152 Id.
153 Id.
154 Increasing Diversity in Clinical Trials: A Collaboration with Tufts Center for the
Study of Drug Development, BIOGEN, https://www.biogen.com/en_us/stories/tufts-clinical-trial.html (last visited Sept. 12, 2021).
155 Id.
150
151
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Pfizer also acknowledges that diversity in clinical trial participants
is “critical to public health and well-being through increased
representation of the populations who experience a condition.”156 To
increase minority patient recruitment, Pfizer is employing community
outreach programs in churches, schools, town halls, and other
community centers to raise awareness and increase education about
clinical trials.157 Realizing the importance of investigator training, Pfizer
also developed a recruitment tracking system to “help establish
diversity as a key scientific variable across [its] research portfolio.”158
While these initiatives represent a good start, to most effectively
increase diversity in clinical trials, the medical community must be
rebuilt to invite trust and confidence from minority populations.159
Members of the medical and healthcare professions must remember the
medical field’s legacy of exploitation and experimentation and its lasting
effects when caring for patients from minority communities. Patients
often have racial preferences in healthcare, and providers should
strongly consider these preferences to optimize care quality.160 Studies
have shown that the effects of implicit bias may be countered when
providers accommodate patients’ physicians’ racial preferences.161
V. PROPOSAL FOR A NEW REGULATION
Since the guidance documents are nonbinding,162 drug developers
have no legal obligation to comply with the FDA’s suggested courses of
action. Demographic data shows that despite various FDA guidances,
diversity in trials still fails to adequately represent the demographics of
those impacted by specific diseases.163 Utilizing its power to regulate
Tina Pavane, Diversity in Clinical Trials: Why It’s Important, PFIZER, https://
www.pfizer.com/news/featured_stories/featured_stories_detail/diversity_in_clinical_trials_why_it_s_important (last visited Sept. 21, 2021).
157 Id.
158 Id.
159 Frederick et al., supra note 9.
160 Kimani Paul-Emile, Patients’ Racial Preferences and the Medical Culture of
Accommodation, 60 UCLA L. REV. 462, 486–87 (2012) (“A patient must be willing to
speak candidly about personal and potentially uncomfortable or embarrassing
information; to submit to bodily examination, including attention to all manner of injury
and abuse; to confide in and communicate openly with the physician; to rely on the
physician’s recommendations; and to feel confident in the belief that the physician is
acting to advance the patient’s best interest. In fact, the absence of these elements may
mean the difference between life and death for some patients. To this end, the AMA has
consistently and unequivocally maintained that a patient’s ability to choose a personal
physician is a ‘prerequisite of optimal care and ethical practice.’” (Citations omitted.)).
161 Id. at 490.
162 2020 GUIDANCE DOCUMENT, supra note 116.
163 See supra Part II.
156
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clinical trials from the Federal Food, Drug, and Cosmetic Act, the FDA
should issue a rule mandating increased diversity in clinical trial
participants when feasible and clinically appropriate as a condition of
obtaining marketing authorization.
Many have criticized the FDA’s attempts to address diversity in
clinical trials and have urged for more compelling action. In a white
paper report about increasing minority participation in clinical trials,
the Endocrine Society asserted that the FDA should require rather than
recommend adherence to its guidelines.164 During the public comment
period following the issuance of the Draft Guidance for the 2020
Guidance Document,165 many of the comments from drug developers,
clinical trial organizations, and patients criticized the document for its
lack of “definition and depth,” insisting that the FDA needs to provide
more clarity about how to determine a clinically appropriate participant
sample.166 One organization specifically “lamented the fact that ‘there is
no direct mention of race and ethnicity’ in the draft guidance, leaving it
to the industry to guess what the FDA means by underrepresented and
minority groups.”167 The organization further said that “[t]he guidance
should provide direction specific to involving African Americans,
Latin[x] and Asians.”168
In 2017, the National Black Church Initiative (NBCI) called upon
the FDA to require diverse participation before approving new drugs or
medical devices.169 Writing to the FDA Commissioner, the NBCI asserted
that “the pharmaceutical community is not going to improve minority
participation in clinical trials until the FDA compels them to do so via
regulations.”170 In a 2008 report, the Eliminating Disparities in Clinical
Trials (EDICT) Project, a collaboration of representatives from public,
private, and non-profit sectors argued that the FDA should “strengthen
its policy to require appropriate inclusion of underrepresented
populations in all clinical trials; [i]mplement penalties for noncompliance with inclusion policies in clinical trials; [and] [i]mplement
incentives for appropriate inclusion of all underrepresented
ENDOCRINE SOCIETY, supra note 28, at 27.
See supra Section IV.A.ii.
166 Colin Stoecker, Industry Seeks More Detail from FDA Guidance on Trial Diversity,
CENTERWATCH (Aug. 19, 2019), https://www.centerwatch.com/articles/12265-industry-seeks-more-detail-from-fda-guidance-on-trial-diversity.
167 Id.
168 Id.
169 Caroline Chen & Riley Wong, Black Patients Miss Out on Promising Cancer Drugs,
PROPUBLICA (Sept. 19, 2018, 5:00 AM), https://www.propublica.org/article/black-patients-miss-out-on-promising-cancer-drugs.
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populations in clinical trials.”171 An FDA spokeswoman maintained that
the FDA “‘does not have the regulatory authority to require specific
levels of minority representation in clinical trials’”—which, while true—
does not prevent the FDA from demanding more generalized
requirements.172
For these reasons, the FDA should promulgate an administrative
rule that will place a legally enforceable duty on drug developers to
increase diversity in clinical trials when feasible and clinically
appropriate. The procedural requirement would be an expansion of the
NIH policy requiring the inclusion of minority groups not just in studies
funded by the NIH, but to all clinical trials under FDA purview.173 The
procedure would be as follows: when an IND is submitted to the FDA for
a drug to advance from Phase II to Phase III of development, data must
be submitted to the FDA detailing any significant demographic-based
differences in safety or efficacy. In addition to demographic-based
safety and efficacy information, the IND must identify the demographics
of the trial participants compared to the demographics of those
generally affected by the disease. If there is a significant lack of diversity
compared to the demographics of those generally affected by the
disease, then the drug developer must provide reasons why and explain
what steps were taken (community outreach, site diversification, etc.)
to enroll diverse trial participants. Alternatively, the drug developers
can show that although they consulted with members of minority
communities about participating in the trial, these individuals made the
choice not to participate.174 The FDA can use its power to place a clinical
hold and suspend an ongoing trial175 if it believes that the sponsor failed
to make sufficient attempts to enroll diverse trial participants.
Proportionate diversity levels need not be reached if enrolling
diverse participants proves too difficult despite best efforts, or if
participants opt not to enroll in trials despite recruitment efforts.
Sponsors, however, will bear the burden of proving that they made a
“good faith effort” to recruit diverse trial participants. To do so,
171 ARMIN D. WEINBERG, THE EDICT PROJECT: POLICY RECOMMENDATIONS TO ELIMINATE
DISPARITIES IN CLINICAL TRIALS 11 (2008), https://www.researchgate.net/publication/
320036453_The_EDICT_Project_Policy_Recommendations_to_Eliminate_Disparities_in_
Clinical_Trials.
172 Chen & Wong, supra note 169.
173 See supra Section IV.A.i.
174 Participating in a clinical trial is a patient’s choice, and drug developers should not
feel incentivized to use coercive tactics to enroll diverse participants. Informed Consent
for Clinical Trials, U.S. FOOD & DRUG ADMIN. (Jan. 4, 2018), https://www.fda.gov/patients/clinical-trials-what-patients-need-know/informed-consent-clinical-trials.
175 See supra Part III.
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sponsors should generally be required to open their trials at facilities
that largely serve minority communities. Sponsors should also have a
certain budget dedicated to community outreach. Evidence showing a
“good faith effort” may also be supported by an increased number of
principal investigators from minority communities or proof that
minority patients were counseled or signed consent to participate in a
clinical trial, but subsequently were found ineligible or for another
reason decided not to participate in the trial. Once that burden is met,
the FDA may continue with its current review procedures.
Of course, there needs to be a balance between increasing diversity
and maintaining an expeditious drug approval process. With COVID-19,
for example, the government has a significant interest in fast tracking
the vaccine development process. Called “Operation Warp Speed,” the
goal was to manufacture and deliver 300 million doses of a safe and
effective vaccine by January 2021.176 Though adding a diversity
requirement may initially slow a study’s progress due to minorities’
distrust of the medical community,177 there will be no “shortages” of
potentially eligible patients that would dramatically slow drug
development. After all, instances of COVID-19 and other diseases are
much higher in minority communities. Even so, as a safeguard, lack of
diversity would not necessarily impede approval: the FDA could
discharge the requirement at its discretion in light of other competing
interests.
This regulation would be an important first step towards removing
health disparities and generally improving health outcomes for
minority communities. We cannot undermine the importance of
knowing that the government is looking out for minority communities’
best interests and no longer standing passively by. By failing to
introduce any binding regulations, government agencies have sent a
clear message that the battle for equality is not one they will help fight.
This deepens the disparities and feelings of isolation among minority
communities.
VI. CONCLUSION
Pre-existing health disparities have worsened during the COVID19 pandemic, which continues to disproportionately affect minority
communities, including Black Americans, Latinx, and Natives
Americans. Despite this fact, COVID-19 treatment and vaccine trials did
Explaining Operation Warp Speed, U.S. DEP’T OF HEALTH & HUM. SERVS., https://
www.nihb.org/covid-19/wp-content/uploads/2020/08/Fact-sheet-operation-warpspeed.pdf (last visited Sept. 12, 2021).
177 See supra Section II.C.ii.
176
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not reflect the diversity of infected individuals. This is consistent with
the fact that clinical trials generally lack diversity compared to the
population as a whole, with minorities being consistently
underrepresented. As a result, safety and efficacy data frequently do not
reflect racial and ethnic differences and may not provide useful
information for many people using a drug or intervention. COVID-19
treatment and vaccine trials that do not include minority participants
may not be safe or effective in these populations. Understandably,
minority patients may not feel safe pursuing treatment or receiving a
vaccination that has not been proven safe or effective in their
demographic class.
To reduce these health disparities, diversity of clinical trial
participants must increase. While government agencies, including the
NIH and the FDA, have taken some steps towards increasing inclusion
in clinical trials, the FDA is in the best position to enforce change
because the FDA ultimately controls which drugs and vaccines are
approved for commercial use. So far, the FDA has primarily issued nonbinding guidance documents that encourage drug developers to
increase diversity in their trials. These documents suggest steps that
drug developers can take to increase diversity during the participant
recruitment process, as well as how to re-design trials to be more
inclusive. Since this guidance is non-binding, and the FDA continues to
approve drugs that were not tested in a diverse participant population,
drug developers have no real incentive to follow the FDA’s guidance.
The FDA should promulgate an administrative rule requiring drug
developers to increase diversity in their clinical trials before they
approve drugs for general use. This rule would place a procedural
requirement on the drug approval process and put the burden on drug
developers to prove that they have made a “good faith effort” to recruit
diverse trial participants. This rule would be similar to the NIH policy
that requires minority populations to be included in NIH-funded clinical
research unless no significant distinguishable racial or ethnic safety or
efficacy concerns exist. Increasing inclusion of minority populations is
an important step towards reducing health disparities and rebuilding
trust between minority populations and the medical community—goals
with critical importance which cannot be ignored during the COVID-19
pandemic and moving forward.

